Sipuleucel-T
Title: Sipuleucel-T
Additional Names: APC-8015
Trademarks: Provenge (Dendreon)
Literature References: Autologous dendritic cell product loaded ex vivo with the recombinant fusion protein PA2024 consisting of human granulocyte macrophage-colony stimulating factor (GM-CSF) linked to human prostatic acid phosphatase (PAP). Therapeutic vaccine designed to stimulate immunity against PAP expressed on prostate cancer cells. Prepn of target antigen: R. Laus et al., WO 9724438; eidem, US 5976546 (1997, 1999 both to Dendreon); of antigen presenting cells and pharmacology: E. J. Small et al., J. Clin. Oncol. 18, 3894 (2000). Clinical evaluation in androgen-independent prostate cancer: P. A. Burch et al., Prostate 60, 197 (2004); P. F. Schellhammer, R. M. Hershberg, World J. Urol. 23, 47 (2005). Review of development and therapeutic potential: F. H. Valone et al., Cancer J. 7, Suppl. 2, S53-S61 (2001); B. I. Rini, Curr. Opin. Mol. Ther. 4, 76-79 (2002).
Therap-Cat: Antineoplastic, immunomodulator.
Keywords: Antineoplastic; Immunomodulators.

Others monographs:
Penicillin FMontan WaxBitertanolLocust Bean Gum
DioxethedrinePiloty's AcidHemicholiniumAtracurium Besylate
RonidazoleTrehalosePhosphorus TriselenideMethylhydrazine
DichloneTungstic(VI) AcidSodium HypophosphiteSpectinomycin
©2016 DrugLead US FDA&EMEA